TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06544746

Intervention type: RADIATION
Intervention: Periapical radiographs
Description: oral radiographs taken with the paralleling technique and film holders at 1- and 3-years post-prosthesis insertion with an X-ray apparatus equipped with a long cone and a Rinn Universal Collimator (Dentsply RINN, York, PA, USA). All radiographs were stored on a PC and analyzed with the software program DBSWIN software. Each radiograph was calibrated using the implant diameter and length as reference measures to correct any distortion before measurement. An image processing program was employed to quantify peri-implant MBL, the EA, EP.

Intervention type: RADIATION
Intervention: Periapical radiographs
Description: oral radiographs taken with the paralleling technique and film holders at 1- and 3-years post-prosthesis insertion with an X-ray apparatus equipped with a long cone and a Rinn Universal Collimator (Dentsply RINN, York, PA, USA). All radiographs were stored on a PC and analyzed with the software program DBSWIN software. Each radiograph was calibrated using the implant diameter and length as reference measures to correct any distortion before measurement. An image processing program was employed to quantify peri-implant MBL, the EA, EP.
Study: NCT05358990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain Language Recommendation (PLR)
Description: New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Language Version (SLV)
Description: Original recommendation as initially published by the guideline organization.
Study: NCT06248684

Intervention type: OTHER
Group type: OTHER
Intervention: standardized prevention and therapy measures
Description: Patients from the age of 65 years with an additional risk factor for postoperative delirium are assigned to a multidimensional standardized perioperative care protocol.
Study: NCT04666610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points to maintain the blinding.
Study: NCT05473299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeltis Hemodialysis Access (aXess) graft
Description: The aXess graft is a sterile, regenerative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
Study: NCT05645757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 6777
Description: A combination of ertapenem (ERT) and zidebactam (ZID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 6777
Description: A combination of ertapenem (ERT) and zidebactam (ZID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 6777
Description: A combination of ertapenem (ERT) and zidebactam (ZID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidebactam
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidebactam
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidebactam
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidebactam
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidebactam
Description: A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
Study: NCT06087588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%sodium chloride
Description: PENG sham block with 20ml 0,9% normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 95% ethanol
Description: PENG neurolysis with 2.5ml of 95% ethanol
Study: NCT06120491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone Acetate
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darolutamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Oral
Study: NCT06559618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phage Therapy
Description: A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% saline solution also 20 mL, followed with a 10 mL flush of the same solution.
Study: NCT06153355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3839840
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3839840
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3839840
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3839840
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3839840
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3839840
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05594238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Engagement
Description: Brief phone session with a study counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Engagement
Description: Brief phone session with a study counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Engagement
Description: Brief phone session with a study counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Engagement
Description: Access to a virtual portal where participant messages with study counselors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Engagement
Description: Access to a virtual portal where participant messages with study counselors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Engagement
Description: Access to a virtual portal where participant messages with study counselors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI-CBT
Description: 8 one-on-one sessions done over the phone or video chat with a study counselor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI-CBT
Description: 8 one-on-one sessions done over the phone or video chat with a study counselor
Study: NCT06225596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT8009
Description: Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + cisplatin Or carboplatin
Description: Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
Study: NCT05175105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets or granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets or granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat-matching placebo
Description: Tablets or granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat-matching placebo
Description: Tablets or granules
Study: NCT06084884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD5851
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851.~During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion.
Study: NCT06170671

Intervention type: DRUG
Intervention: Non interventional study
Description: CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection

Intervention type: DRUG
Intervention: Non interventional study
Description: CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection
Study: NCT06071715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVE cryoneurolysis
Description: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVE cryoneurolysis
Description: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM cryoneurolysis
Description: SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM cryoneurolysis
Description: SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
Study: NCT04471246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: 1000 mg PO QID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin + placebo
Description: 500 mg PO QID plus oral placebo for 7 days
Study: NCT05624996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05342883

Intervention type: DEVICE
Group type: OTHER
Intervention: Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)
Description: At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
Study: NCT06083246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybenix gel
Description: Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlosite gel
Description: Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
Study: NCT06438302

Intervention type: DEVICE
Intervention: EEG activity measurement
Description: The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 31°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition.